$31m in new funds to help Cebix progress novel peripheral neuropathy candidate

San Diego-based Cebix has closed a $30.9 million Series B venture capital financing round to fund Phase IIb development for the company's C-peptide replacement therapy Ersatta, which may become the first disease-modifying treatment for peripheral neuropathy in type 1 diabetes patients.

San Diego-based Cebix has closed a $30.9 million Series B venture capital financing round to fund Phase IIb development for the company's C-peptide replacement therapy Ersatta, which may become the first disease-modifying treatment for peripheral neuropathy in type 1 diabetes patients.

Several companies have sought regulatory approvals for drugs that reduce the pain of diabetic peripheral neuropathy, rather than develop therapies...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category